« Previous article
New Identity Reflect...

2nd March 2020  Editorial by: Paul Carton

WuXi Launch Covid-19 ELISA & NAT Diagnostic Kits

Wuxi Diagnostics has developed two ELISA-method Covid-19 antibody detection kits along with a nucleic-acid test (NAT) for the novel coronavirus.

The ELISA-method 2019 New Coronavirus (2019-nCoV) IgM Antibody Detection Kit, and the IgM / IgG Antibody Detection Kit can detect specific IgM and IgG antibodies in serum samples within 60 minutes with high reproducibility. 

The 2019 New Coronavirus (2019-nCoV) Nucleic Acid Detection Kit (PCR-Fluorescent Probe Method) is based on the latest sequence variation studies. The kit utilizes quantitative fluorescence PCR combined with a TaqMan probe with high specificity to ensure accurate identification of ORF1ab and N genes of 2019-nCoV. The assay is optimized with an internal control to exclude false-negative results from sample inhibitors and amplification failures. The kit can be used for the detection of 2019-nCoV infection in different types of samples, such as nasopharyngeal swabs, alveolar lavage fluid, sputum, etc. It can also provide the result as soon as two hours from processing a sample.

"All these products, as a set of 'integrated detection' solutions, assist medical institutions in diagnosing COVID-19 infection quickly and accurately and improving epidemic prevention and control capabilities for disease control centres at all levels. Performing just one type of test to diagnose COVID-19 could lead to a false-negative result or misdiagnosis due to complex medical conditions of the patients.

Therefore, implementation of a combined diagnostic workflow by integrating serological and molecular tests using the three 2019-nCoV viral detection kits developed by WuXi Diagnostics will provide a comprehensive diagnosis for clinicians", advised Wuxi Diagnostics, in the product's associated press release.



Date Published: 2nd March 2020

Source article link: View

View full company details